

## **Taxol (paclitaxel)**

### **RECOMMENDED CHANGES TO THE PRODUCT INFORMATION**

The following changes to the product information of medicinal products containing the active substance paclitaxel are recommended:

#### **Summary of product characteristics**

- Section 4.8

The following adverse reaction should be added under the SOC Blood and lymphatic system disorders with a frequency unknown: disseminated intravascular coagulation

[In addition, the safety information regarding alopecia should be updated in line with the SmPC of Abraxane.](#)

#### **Package leaflet**

Please ensure that the proposed changes to the SmPC are adequately reflected, in lay terms, in the package leaflet.